Bionovo’s VG101 Shows Greater Efficacy Than Estrogen In The Treatment Of Vaginal Dryness
Oct 1st 2008Drug InformationEndocrinology
Bionovo, Inc. (Nasdaq: BNVI) will present an abstract in a presentation on their new drug candidate, VG101, for the treatment of vaginal dryness, at the 19th Annual Meeting of the North American Menopause Society in Orlando, Florida on September 26, 2008. Dr. Mary Tagliaferri, president and chief medical officer of Bionovo, will provide seminal information on the company’s second estrogen receptor beta selective drug candidate that will be entering clinical trials shortly.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
